Transaction overview
Novolex, a leading U.S.-based company specializing in sustainable food packaging solutions, completed its acquisition of Pactiv Evergreen for $6.7 billion in an all-cash transaction on December 9, 2024. The deal was announced on December 1, 2024. Pactiv Evergreen is a prominent player in the consumer sector, providing various food packaging products and services.
Deal structure and financing
The acquisition of Pactiv Evergreen by Novolex was fully financed through cash, with Apollo Funds playing a significant role as an equity provider. The exact split between debt and equity financing has not been disclosed publicly. Lead banks involved included Barclays, Goldman Sachs, and Lazard. While leverage metrics have not been released, given the size of the transaction, it is likely that a substantial portion was funded through bank loans or other forms of debt. There are no reports of any seller-retained stake from Pactiv Evergreen's shareholders. Additionally, lock-up terms for key executives were not disclosed as part of the deal announcement. The acquisition does not include any IPO optionality and was structured purely as an all-cash transaction.
Strategic context
Novolex's acquisition of Pactiv Evergreen underscores its strategic commitment to expanding its portfolio with complementary packaging solutions while reinforcing its environmental stewardship goals. This move allows Novolex to diversify its product offerings, enhancing its competitiveness in the food packaging market. Pactiv Evergreen brings a strong presence in various consumer products and services that align well with Novolex’s sustainability focus.
Pactiv Evergreen's decision to divest was likely driven by strategic priorities focused on streamlining operations and focusing resources on core business areas. The acquisition also represents a continuation of Apollo Funds' active investment approach, aiming for transformative growth within the packaging industry. Valuation benchmarks suggest that the $6.7 billion price tag reflects competitive market conditions but aligns with comparable transactions in recent years involving similar-sized acquisitions in the consumer goods sector.
Regulatory path
The deal between Novolex and Pactiv Evergreen was subject to regulatory review primarily in the United States, given both companies' significant operations within U.S. jurisdictions. To date, no specific remedies have been required or announced by antitrust authorities such as the Federal Trade Commission (FTC) or the Department of Justice (DOJ). The Hart-Scott-Rodino (HSR) Act filing was made on December 1, 2024, which is the same day as the deal announcement. Given the transaction's scale and industry impact, thorough scrutiny from U.S. regulators was expected, though no significant delays or challenges were reported during the review process.